Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Foerster, Robert ^a   Kluck, Robert ^a   Rief, Harald ^a   Rieken, Stefan ^a   Debus, Juergen ^a   Lindel, Katja ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Clear cell; Endometrial cancer; Papillary serous; Radiotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SEVERITY; DISTANT METASTASIS FREE SURVIVAL; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE DISSECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TYPE II ENDOMETRIAL CARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADJUVANT THERAPY; CANCER STAGING; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RADIATION DOSE; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 84902301874     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-141     Document Type: Article

References (27)

1. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009, 16:46-52.
2. Boruta DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009, 115:142-153. 10.1016/j.ygyno.2009.06.011, 19592079.
3. Greggi S, Mangili G, Scaffa C, Scala F, Losito S, Iodice F, Pisano C, Montoli S, Vigano R, Pirozzi G, Giannarelli D. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. Int J Gynecol Cancer 2011, 21:661-667. 10.1097/IGC.0b013e3182150c89, 21412164.
4. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94:642-646. 2361201, 16495918.
5. Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL. Pilot phase II trial of radiation " sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2008, 108:201-206. 10.1016/j.ygyno.2007.09.025, 17997145.
6. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011, CD003175.
7. Morneau M, Foster W, Lalancette M, Van Nguyen-Huynh T, Renaud MC, Samouelian V, Letarte N, Almanric K, Boily G, Bouchard P, Boulanger J, Cournoyer G, Couture F, Gervais N, Goulet S, Guay MP, Kavanagh M, Lemieux J, Lesperance B, Letarte N, Morneau M, Ouellet JF, Pineau G, Rajan R, Roy I, Samson B, Sideris L, Vincent F. Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comite de l'evolution des pratiques en oncologie (CEPO). Gynecol Oncol 2013, 131:231-240. 10.1016/j.ygyno.2013.07.084, 23872191.
8. Kim HJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol 2013, 24:120-127. 10.3802/jgo.2013.24.2.120, 3644687, 23653828.
9. Scarfone G, Secomandi R, Parazzini F, Vigano R, Mangili G, Frigerio L, Villa A, Tateo S, Ricci E, Bolis G. Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases. Arch Gynecol Obstet 2013, 287:351-356. 10.1007/s00404-012-2586-x, 23100038.
10. Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U. The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol 2011, 123:542-547. 10.1016/j.ygyno.2011.09.005, 21963091.
11. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009, 105:103-104. 10.1016/j.ijgo.2009.02.012, 19367689.
12. Craighead PS, Sait K, Stuart GC, Arthur K, Nation J, Duggan M, Guo D. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol 2000, 77:248-253. 10.1006/gyno.2000.5746, 10785473.
13. Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol 2012, 127:321-325. 10.1016/j.ygyno.2012.07.112, 22850412.
14. Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villa S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 2008, 108:298-305. 10.1016/j.ygyno.2007.10.037, 18096209.
15. Yechieli R, Rasool N, Robbins JR, Cogan CM, Elshaikh MA. Adjuvant radiation therapy for patients with type II endometrial carcinoma: impact on tumor recurrence and survival. Int J Gynecol Cancer 2013, 23:763-768. 10.1097/IGC.0b013e31828b15cb, 23485931.
16. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, Steen-Banasik E, Beerman H, van LM. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000, 355:1404-1411. 10.1016/S0140-6736(00)02139-5, 10791524.
17. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003, 55:1272-1276. 10.1016/S0360-3016(02)04404-8, 12654437.
18. Fader AN, Drake RD, O'Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, Gehrig PA, Tuller E, Axtell AE, Zanotti KM. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009, 115:2119-2127. 10.1002/cncr.24247, 19306417.
19. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer 2010, 46:2422-2431. 10.1016/j.ejca.2010.06.002, 3552301, 20619634.
20. Thanapprapasr D, Cheewakriangkrai C, Likittanasombut P, Thanapprapasr K, Mutch DG. Targeted endometrial cancer therapy as a future prospect. Womens Health (Lond Engl) 2013, 9:189-199. 10.2217/whe.13.4, 23477324.
21. Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, Kapp DS, Kapp DS. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006, 107:1823-1830. 10.1002/cncr.22185, 16977653.
22. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol 2010, 22:21-29. 10.1097/GCO.0b013e328334d8a3, 19952744.
23. Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol 2001, 81:279-286. 10.1006/gyno.2001.6159, 11330963.
24. del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 2012, 127:651-661. 10.1016/j.ygyno.2012.09.012, 23000148.
25. Vance S, Yechieli R, Cogan C, Hanna R, Munkarah A, Elshaikh MA. The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma. Gynecol Oncol 2012, 126:16-19. 10.1016/j.ygyno.2012.04.011, 22507535.
26. Weber SK, Sauerwald A, Polcher M, Braun M, Debald M, Serce NB, Kuhn W, Brunagel-Walgenbach G, Rudlowski C. Detection of lymphovascular invasion by D2-40 (podoplanin) immunoexpression in endometrial cancer. Int J Gynecol Cancer 2012, 22:1442-1448. 10.1097/IGC.0b013e318269139b, 22964524.
27. Weinberg LE, Kunos CA, Zanotti KM. Lymphovascular Space Invasion (LVSI) Is an Isolated Poor Prognostic Factor for Recurrence and Survival Among Women With Intermediate- to High-Risk Early-Stage Endometrioid Endometrial Cancer. Int J Gynecol Cancer 2013, 23:1438-1445. 10.1097/IGC.0b013e3182a16c93, 24257558.